Skip to content
‹ Back to IndustriesHealthcare

New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Bon Secours Mercy Health agrees to buy surgery center chain Surgery Partners for $5.7 billion

Bon Secours Mercy Health agrees to buy surgery center chain Surgery Partners for $5.7 billion

Bon Secours Mercy Health affiliate HealthSpan Partners agreed to acquire Surgery Partners in a $5.7 billion deal. The chain reported $3.31 billion in revenue during 2025, according to Fierce Healthcare. Insurers in its 30 states may face a bigger negotiator.

  • 01Surgery Partners reported $3.31 billion in revenue for 2025, while Bon Secours Mercy Health reported just under $14 billion, according to Fierce Healthcare. That suggests outpatient surgery could become a major part of the system's business.
  • 02The signal to watch after the Q1 2027 close: whether surgery center rates get folded into the system's broader negotiations with commercial insurers in its 30-state footprint.

Nov 2, 2026

Why CAHPS still swings Star Ratings at half its old weight

Why CAHPS still swings Star Ratings at half its old weight

mPulse’s Sam Oliver and Reva Sheehan said the CAHPS chapter moved with overall Medicare Advantage Star Ratings from 2026 to 2027 after CMS cut its weight from 4 to 2. With 11 measures slated to exit by 2029 and the equity reward cancelled, they urged quality teams to model CAHPS impacts and population mix alongside reweighting changes.

  • 01CMS cut CAHPS from a weight of 4 to 2 in the CY2025 final rule, effective with the 2026 Star Ratings, yet mPulse's chapter data shows CAHPS still moved in the same direction as overall stars for the 2027 cycle.
  • 02The April 2026 final rule removes 11 administrative measures, but none leave before the 2028 Star Ratings; the 2027 measure set is unchanged and the Health Equity Index reward is cancelled.
  • 03CAHPS stars are set by percentile cutoffs and reliability tests, and in the 2025 Star Ratings 13 percent of CAHPS results landed on a different star than the cutoff implied, 93 percent of them lower, according to RISE Health.

Nov 2, 2026

Why ECG device makers may stop rebuilding arrhythmia analysis from scratch

Why ECG device makers may stop rebuilding arrhythmia analysis from scratch

Monebo's Kinetic Software Library provides ectopic beat detection, QRS feature extraction, and heart rate and rhythm analysis for ECG devices. For ECG device engineering and regulatory teams, rhythm analysis could become a choice between building it and licensing it.

  • 01Fifty-one later FDA clearances trace their predicate lineage to Monebo's earlier libraries, a track record anyone evaluating the new one can check.

Nov 1, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512